World & BusinessNovo Nordisk reportedly signs Nanexa drug-delivery deal worth up to €1.165 billion
Bloomberg reports that the agreement covers rights to the Swedish company’s drug-delivery technology for obesity and diabetes treatments.
TLDR
Novo Nordisk signed a deal with Sweden’s Nanexa worth as much as €1.165 billion ($1.3 billion), Bloomberg reports. The agreement is for rights to Nanexa’s drug-delivery technology for obesity and diabetes treatments.
Novo Nordisk reportedly signs Nanexa drug-delivery deal worth up to €1.165 billion
Bloomberg reports that the agreement covers rights to the Swedish company’s drug-delivery technology for obesity and diabetes treatments.